You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 6,083,909

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,083,909

Title:	Haemoglobin-hydroxyethyl starch conjugates as oxygen carriers
Abstract:	The present invention relates to new oxygen transfer agents which comprise haemoglobin-hydroxyethylstarch conjugates, and processes for their preparation. The invention furthermore relates to the use of the oxygen transfer agents as a blood substitute, plasma expander, perfusion agent, haemodilution agent and/or cardioplegic solution. The invention relates in particular to oxygen transfer agents which comprise a haemoglobin-hydroxyethylstarch conjugate in which the haemoglobin and the hydroxyethylstarch are linked to one another selectively via amide bonds between free amino groups of the haemoglobin and the reducing end group of the hydroxyethylstarch, which is present in oxidized form.
Inventor(s):	Sommermeyer; Klaus (Rosbach, DE), Eichner; Wolfram (Butzbach, DE)
Assignee:	Fresenius AG (Oberusel, DE)
Application Number:	09/214,430
Patent Claims:	1. Oxygen transfer agent comprising a haemoglobin-hydroxyethylstarch conjugate, characterized in that the haemoglobin and the hydroxyethylstarch in the conjugate are linked to one another selectively via amide bonds between free amino groups of the haemoglobin and the reducing end group of the hydroxyethylstarch, which is present in oxidized form. 2. Oxygen transfer agent according to claim 1, characterized in that the haemoglobin-hydroxyethylstarch conjugate is present in the oxygen transfer agent in a concentration of between 2 and 20 g/dl. 3. Oxygen transfer agent according to claim 2, characterized in that the haemoglobin-hydroxyethylstarch conjugate is present in the oxygen transfer agent in a concentration of between 5 and 20 g/dl. 4. Oxygen transfer agent according to claim 1, characterized in that the haemoglobin is of human, animal, vegetable or recombinant origin. 5. Oxygen transfer agent according to claim 1, characterized in that the haemoglobin is of bovine origin. 6. Oxygen transfer agent according to claim 1, characterized in that before linking the hydroxyethylstarch, the haemoglobin is present as deoxy-haemoglobin or as a mixture of deoxy-haemoglobin and haemoglobin in a CO--, O.sub.2 -- or met-haemoglobin derivative state. 7. Oxygen transfer agent according to claim 1, characterized in that before linking the hydroxyethylstarch, the haemoglobin is present as a mixture of deoxy-haemoglobin and oxy-haemoglobin, the content of deoxy-haemoglobin being 20 to 80% and the content of haemoglobin in a CO--, O.sub.2 -- or met-haemoglobin derivative state being 80 to 20%. 8. Oxygen transfer agent according to claim 1, characterized in that the haemoglobin is crosslinked and/or polymerized haemoglobin. 9. Oxygen transfer agent according to claim 1, characterized in that the hydroxyethylstarch has an average molecular weight of 1 to 40 kDa. 10. Oxygen transfer agent according to claim 1, characterized in that the hydroxyethylstarch has an average molecular weight of 2 to 20 kDa. 11. Oxygen transfer agent according to claim 1, characterized in that the hydroxyethylstarch has a molar degree of substitution of 0.1 to 0.8 and a ratio of C.sub.2 :C.sub.6 substitution in the range from 2 to 20, based on the hydroxyethyl groups. 12. Oxygen transfer agent according to claim 1, characterized in that the agent furthermore comprises albumin. 13. Oxygen transfer agent according to claim 12, characterized in that the albumin is serum albumin of human, animal, vegetable or recombinant origin. 14. Oxygen transfer agent according to claim 12, characterized in that the albumin is present in a concentration of between 2 and 20 g/dl. 15. Oxygen transfer agent according to claim 12, characterized in that the weight ratio of the haemoglobin-hydroxyethylstarch conjugate to albumin is in the range from 1:10 to 4:1. 16. Oxygen transfer agent according to claim 12, characterized in that before addition to the conjugate, the albumin is present in an aqueous solution saturated with nitrogen monoxide (NO). 17. Oxygen transfer agent according to claim 1, characterized in that the agent is present as an aqueous solution or as a lyophilisate. 18. Process for the preparation of an oxygen transfer agent comprising a haemoglobin-hydroxyethylstarch conjugate, characterized in that the reducing end groups of hydroxyethylstarch are first oxidized and haemoglobin is then coupled to the oxidized end groups of the hydroxyethylstarch via free amino groups by means of amide bonds. 19. Process according to claim 18, characterized in that the oxidation of the reducing end groups of the hydroxyethylstarch is carried out by first mixing the hydroxyethylstarch with an iodine-containing solution and then adding potassium hydroxide solution. 20. Process according to claim 18, characterized in that the coupling of the free amino groups of the haemoglobin with the reducing end groups of the hydroxethylstarch which are present in oxidized form is carried out by mixing the individual components at 40.degree. C. 21. Process according to claim 18, characterized in that the haemoglobin is of human, animal, vegetable or recombinant origin. 22. Process according to claim 18, characterized in that the haemoglobin is of bovine origin. 23. Process according to claim 18, characterized in that before the coupling to the hydroxyethylstarch, the haemoglobin is present as deoxy-haemoglobin or as a mixture of deoxy-haemoglobin and haemoglobin in a CO--, O.sub.2 -- or met-haemoglobin derivative state. 24. Process according to claim 18, characterized in that before the coupling to the hydroxyethylstarch, the haemoglobin is present as a mixture of deoxy-haemoglobin and haemoglobin in a CO--, O.sub.2 -- or met-haemoglobin derivative state, the content of deoxy-haemoglobin being 20 to 80% and the content of haemoglobin in said derivative state being 80 to 20%. 25. Process according to claim 18, characterized in that the haemoglobin is crosslinked and/or polymerized haemoglobin. 26. Process according to claim 18, characterized in that the hydroxyethylstarch has an average molecular weight of 5 to 40 kDa, a molar degree of substitution of 0.1 to 0.8 and a ratio of C.sub.2 :C.sub.6 substitution in the range from 2 to 20, based on the hydroxyethyl groups. 27. A method of treating a mammal in need of an oxygen transfer comprising administering an oxygen transfer agent according to claim 1 or an oxygen transfer agent prepared according to claim 18 with a blood substitute, plasma expander, perfusion agent, haemodilution agent and/or cardioplegic solution to said mammal.

Details for Patent 6,083,909

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2016-07-08
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2016-07-08
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2016-07-08
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.